ALDAGEN is currently conducting clinical trials for four product candidates, including ALD-101 which is in a pivotal Phase 3 trial to improve cord blood transplants for pediatric patients with inherited metabolic diseases. They are also conducting or supporting trials for ALD-151 to improve cord blood transplants for leukemia treatment, ALD-301 for critical limb ischemia, and ALD-201 for ischemic heart failure. The company's proprietary products identify and isolate adult stem cells to regenerate or repair tissue, with a focus on cardiovascular and degenerative diseases.